Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

NCT00749567 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Bevacizumab

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]